Parkinson disease: Nursing process (ADPIE)

1,856views

Parkinson disease: Nursing process (ADPIE)

SHRAVAM

SHRAVAM

Gastrointestinal system anatomy and physiology
Fractures: Nursing process (ADPIE)
Anaphylaxis: Nursing process (ADPIE)
Lyme disease: Nursing process (ADPIE)
Vaccines: Nursing pharmacology
Immunoglobulins: Nursing pharmacology
Immunosuppressants for autoimmune diseases: Nursing pharmacology
Appendicitis: Nursing process (ADPIE)
Celiac disease: Nursing process (ADPIE)
Cirrhosis: Nursing process (ADPIE)
Gastroesophageal reflux disease (GERD): Nursing process (ADPIE)
Hiatal hernia: Nursing process (ADPIE)
Pancreatitis: Nursing process (ADPIE)
Peptic ulcer disease (PUD): Nursing process (ADPIE)
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Laxatives: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Antiemetics: Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Cholinergic therapy (GU): Nursing pharmacology
Diabetes insipidus: Nursing process (ADPIE)
Diabetes mellitus (DM): Nursing process (ADPIE)
Diabetic ketoacidosis (DKA): Nursing process (ADPIE)
Hyperosmolar hyperglycemic state (HHS): Nursing process (ADPIE)
Hyperthyroidism: Nursing process (ADPIE)
Hypothyroidism: Nursing process (ADPIE)
Syndrome of inappropriate antidiuretic hormone (SIADH): Nursing process (ADPIE)
Medications for antidiuretic hormone (ADH) disorders: Nursing pharmacology
Medications for thyroid disorders: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Insulin: Nursing pharmacology
Epistaxis: Nursing process (ADPIE)
Eye injury: Nursing process (ADPIE)
Glaucoma: Nursing process (ADPIE)
Tonsillitis: Nursing process (ADPIE)
Antiglaucoma medications: Nursing pharmacology
Eye anesthetics: Nursing pharmacology
Mydriatics and cycloplegics: Nursing pharmacology
Ophthalmic anti-inflammatories and anti-infectives: Nursing pharmacology
Acute compartment syndrome: Nursing process (ADPIE)
Gout: Nursing process (ADPIE)
Musculoskeletal injuries: Nursing process (ADPIE)
Rheumatoid arthritis (RA): Nursing process (ADPIE)
Acetylcholinesterase inhibitors for myasthenia gravis: Nursing pharmacology
Analgesics: Nursing pharmacology
Antiepileptics: Nursing pharmacology
Medications for Alzheimer disease: Nursing pharmacology
Skeletal muscle relaxants: Nursing pharmacology
Meningitis: Nursing process (ADPIE)
Parkinson disease: Nursing process (ADPIE)
Seizure disorder: Nursing process (ADPIE)
Stroke: Nursing process (ADPIE)
Trigeminal neuralgia: Nursing process (ADPIE)
Breast cancer: Nursing process (ADPIE)
Tumor lysis syndrome (TLS): Nursing Process (ADPIE)
Plant extracts for chemotherapy: Nursing pharmacology
Peripheral arterial disease (PAD): Nursing process (ADPIE)
Peripheral venous disease (PVD): Nursing process (ADPIE)
Chickenpox (Varicella): Nursing process (ADPIE)
Conjunctivitis: Nursing process (ADPIE)
Hydrocephalus: Nursing process (ADPIE)
Poisoning: Nursing process (ADPIE)
Pyloric stenosis: Nursing process (ADPIE)
Reye syndrome: Nursing process (ADPIE)
Bronchiolitis and respiratory syncytial virus (RSV): Nursing process (ADPIE)
Pharmacokinetics - Elimination: Nursing pharmacology
Anthelmintics: Nursing pharmacology
Antibiotics - Aminoglycosides: Nursing pharmacology
Antibiotics - Cephalosporins: Nursing pharmacology
Antibiotics - Fluoroquinolones: Nursing pharmacology
Antibiotics - Macrolides: Nursing pharmacology
Antibiotics - Metronidazole: Nursing pharmacology
Antibiotics - Oxazolidinones: Nursing pharmacology
Antibiotics - Tetracyclines and glycylcyclines: Nursing pharmacology
Antibiotics - Trimethoprim and sulfonamides: Nursing pharmacology
Antibiotics - Polymyxins: Nursing pharmacology
Antibiotics - Cyclic lipopeptides: Nursing pharmacology
Antiprotozoals: Nursing pharmacology
Antivirals for herpesviruses: Nursing pharmacology
Antibiotics - Glycopeptides: Nursing pharmacology
Antimalarials: Nursing pharmacology
Antivirals for hepatitis B and C: Nursing pharmacology
Antibiotics - Lincosamides: Nursing pharmacology
Antibiotics - Antimycobacterials: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Beta-adrenergic blockers: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Cardiac glycosides: Nursing pharmacology
Direct-acting vasodilators: Nursing pharmacology

Notes

PARKINSON DISEASE

KEY POINTS
NOTES
PATIENT REPORT
  • 67-year-old
  • History: Parkinson disease (PD)
  • Recently moved into long-term care facility

PATHOPHYSIOLOGY
  • Progressive neurological disease 
  • Affects movement 
  • Risk factors 
    • Non-modifiable 
      • Increasing age 
        • Mean age of onset is 57 years 
      • Biological male sex 
      • Family history of PD 
    • Modifiable 
      • Exposure to toxins 
      • History of head trauma 
  • Pathophysiology 
    • Degeneration of dopamine-producing neurons 
      • Located in substantia nigra 
      • Part of the basal ganglia 
    • Substantia nigra function 
      • Initiates movement 
      • Fine tunes movement 
  • Motor symptoms 
    • Resting tremor 
    • Involuntary shaking at rest 
    • Decreases with movement 
    • Common in hands 
      • "Pill-rolling” tremor 
    • May affect feet, tongue, jaw 
    • Bradykinesia  
    • Akinesia 
    • Cogwheel rigidity  
    • Facial muscle rigidity 
    • Difficulty speaking, chewing, swallowing 
    • Stooped posture 
    • Postural instability 
  • Non-motor symptoms 
    • Urinary incontinence 
    • Constipation 
    • Sleep disturbances 
    • Apathy 
    • Depression 
    • Dementia 
    • Impaired sense of smell

DIAGNOSIS AND TREATMENT
  • Diagnosis
    • History
    • Physical assessment
    • Rule out other potential conditions
    • Diagnostic imaging
  • Treatment
    • No cure  
    • Symptom management 
      • Medications to increase dopamine 
        • Levodopa-carbidopa 
        • COMT inhibitors 
        • MAO-B inhibitors 
        • Dopamine agonists 
      • Deep-brain stimulation 

ASSESSMENT
  • General appearance and behavior 
    • Sitting in armchair with forward leaning posture 
    • Flat affect observed 
    • Slow to respond to questions 
    • Right hand tremor present 
    • Tremor decreases with finger-to-nose test 
  • Mobility and neuromuscular assessment 
    • Ambulates with small, shuffling steps 
    • Stooped posture while walking 
    • Rigidity noted during passive limb movement 
    • Reports minimal mobility 
  • Hydration and nutrition 
    • Mucous membranes tacky and dry 
    • Skin turgor shows tenting 
    • Reports last bowel movement four days ago 
    • Appears thin 
    • Weight loss of 10 lbs (4.5 kg) in 3 months 
    • Eats slowly
    • Difficulty chewing observed
    • Food falls from mouth at times
    • Occasional coughing and gagging
    • Consumes less than half of meal
  • Vital signs 
    • Temperature 98.4 F (36.9 C)
    • Heart rate 85 beats per minute, regular 
    • Respiratory rate 16 breaths per minute 
    • Blood pressure 115/70 mmHg 
    • SpO2 98% room air 

NURSING DIAGNOSES
  • Risk for falls related to gait abnormalities stiff limbs, and stooped posture while ambulating
  • Constipation related to weakness of muscles, lack of physical activity, and inadequate fluid intake
  • Impaired swallowing related to neuromuscular impairment
  • Imbalanced nutrition less than body requirements related to difficulty in chewing and swallowing

PLANNING
  • In one month, patient will
    • Improve nutritional intake
    • Have moist mucous membranes and no skin tenting 
    • Demonstrate effective swallowing 
    • Not experience coughing, gagging, or losing food from mouth while eating
  • In one week
    • Constipation will be resolved as evidenced by a passage of soft, formed stool every 1 to 3 days without straining
  • Long term goal
    • Patient will remain free of falls throughout stay 

IMPLEMENTATION
  • Fall precautions instituted 
  • Physical therapist involvement 
  • Gait training 
  • Strengthening exercises 
  • Balance improvement 
  • Daily range of motion exercises 
  • Begin multivitamin as ordered 
  • Begin stool softener as ordered 
  • Referral to dietitian  
    • Modified diet
      • Increased calories 
      • Increased protein 
      • Increased fiber 
      • Thickened liquids  
      • Small meals or snacks daily 
      • Sit upright during meals 
      • Food cut into small pieces 
  • Speech therapist referral for swallowing issues
  • Monitor oral intake 
  • Monitor bowel habits 
  • Monitor weight weekly 
  • Monitor for neuromuscular deficits 
  • Report changes to HCP

EVALUATION
  • No falls reported 
  • Improved bowel function 
  • Decreased coughing and gagging during meals 
  • Consuming half of meals and snacks 
  • Weight 117.5 lbs (53.2 kg)
  • Hydration status improved 
  • Moist mucous membranes 
  • Normal skin turgor

Transcript

Watch video only

Michael Desante is a 67 year old male with a history of Parkinson disease. His daughter has been his primary caregiver since his diagnosis, however, as Michael’s disease progressed, Michael moved into a long-term care center for further support.

Parkinson disease, or PD for short, is a progressive neurological disease that affects movement. Most often, the cause of PD is unknown, but there are some factors that can increase the risk.

Non-modifiable risk factors include increasing age, with a mean age of onset of 57 years; as well as male sex; and having a family history of PD.

On the other hand, modifiable risk factors include exposure to toxins like pesticides, and a history of head trauma. Now, in PD there’s degeneration of the dopamine-producing neurons in the substantia nigra of the basal ganglia.

Normally, the substantia nigra helps initiate movements, but also fine tunes the way that movements happen. When these neurons die, the first symptom is a resting tremor, which is an involuntary shaking that presents at rest and decreases with movement.

Most often, resting tremor affects the hands, which is called a “pill-rolling” tremor because it looks like someone is rolling a pill between their thumb and index finger.

Over time, resting tremor can also involve the feet, tongue, and jaw. In addition, the client can experience bradykinesia, or slowness of voluntary movement.

A more severe form of bradykinesia is akinesia, which is when they become unable to initiate a voluntary movement. For instance, the client may feel like their legs freeze up when trying to walk.

Another typical symptom is “cogwheel” rigidity, which is a type of stiffness characterized by a series of catches or stalls as a person’s arms or legs are passively moved by someone else.

And because of rigidity of facial muscles, some clients with PD may have a mask-like facial expression, as well as difficulty speaking, chewing, and swallowing.

As a result, food, fluid, or saliva may enter the lungs, causing aspiration pneumonia. Decreased intake can put the client at risk for nutritional problems.

Additionally, clients may acquire a stooped posture, and a late feature of the disease is postural instability, which causes problems with maintaining balance and can lead to falls.

Now, PD can also cause non-motor symptoms, like urinary incontinence and constipation. Finally, some clients may develop sleep disturbances, apathy, depression, dementia, and an impaired sense of smell.

Okay, now diagnosis of PD mainly relies on physical examination and the presence of bradykinesia in addition to at least one of either akinesia, tremor, rigidity, or postural instability.

Ruling out other potential causes is also required. Sometimes, the diagnosis can be confirmed by administering L-dopa, which is a precursor of dopamine.

If the client’s symptoms improve, the diagnosis is confirmed. Another diagnostic test that can be used to confirm diagnosis is the DaT scan, which is an imaging technique that helps visualize the dopamine levels in the brain.

Unfortunately, there’s no cure for PD, but there are medications that can help with its symptoms by increasing the amount of dopamine in the brain. The drug combination levodopa-carbidopa is a common treatment.

Levodopa is a dopamine precursor that’s converted into dopamine in the brain, while carbidopa prevents levodopa from being broken down.

Sometimes these drugs are given in combination with a catechol-O-methyltransferase, or COMT inhibitor, called entacapone, that prevents the breakdown of levodopa by the enzyme COMT.

Very similarly, clients can be given MAO-B inhibitors like selegiline, which prevents the breakdown of dopamine by the enzyme monoamine oxidase B.

Finally, the dopamine agonist amantadine acts by increasing dopamine production. If medications fail to control symptoms or the client develops serious adverse effects, they can be treated with deep-brain stimulation.

This involves an implantable device that sends electrical signals to the brain that counteract the motor symptoms of PD. Okay, let’s get back and assess your client Michael.

After reviewing his chart, you enter his room, introduce yourself to Michael and his daughter, wash your hands, and confirm his identity. Michael is sitting in an armchair in a forward leaning posture.

You ask Michael how he is feeling today, and he replies “OK.” You note that he has a flat affect and is slow to respond to questions. A tremor in his right hand is also present.